Science & Health Digest
TL;DR
The outbreaks all escalated at once: measles hit a 35-year high of 3,887 cases while Florida's dengue outbreak became the largest locally transmitted event in the continental US in decades and H5N1 reached Washington dairy herds. The DRC Ebola outbreak crossed 8,700 cases — the largest ever recorded in the country — with a dead imported case in Kenya and a medevaced responder in the Netherlands. On the regulatory side, the FDA approved atezolizumab for adjuvant dMMR colon cancer on a hazard ratio of 0.50, and told a federal court its mifepristone safety review lands by March 2027.
Measles: the federal posture is now openly two-faced
The federal response to measles has split into real money and real coordination on one side, continued public dispute of state death counts on the other. The national tally hit 3,887 cases as of October 1–2 — the highest since 1990/1991 and already exceeding all of 2025 — while Pennsylvania confirmed a fifth death on September 30, an unvaccinated Lancaster County resident (PA DOH, via the measles finding
+1). The CDC still counts only two of Pennsylvania's five deaths.
The new development is the Hochul channel working. After New York's disaster emergency, HHS said RFK Jr. offered federal support during a Tuesday call and connected her with CDC Director Erica Schwartz. Hochul's spokesperson put it plainly:
"No state can address this on its own, which is why the governor will partner with anyone who can support our efforts to protect New Yorkers."
— Reuters via Yahoo, via the measles finding+1
The contrast with Pennsylvania — which has resisted seeking CDC help after Kennedy disputed its death counts — is now the defining feature of the response. Meanwhile the NYT reports the CDC is offering states $100 million in measles support, so the machinery is funded even as the politics stay loaded. With three months of respiratory season left, losing elimination status at the November PAHO review is the default expectation.
What to watch: Whether the CDC tally absorbs Pennsylvania's five deaths before the November review — and whether Texas and Virginia's CDC-assistance requests, unlike Pennsylvania's, proceed without friction.
Dengue: Tampa Bay's outbreak is now bigger than any recent year, and the emergency orders came due
Florida's dengue event crossed a threshold this week: 296 locally acquired cases in 2026 against just 62 in all of 2025, with 44 new cases in the first week of October alone. The geography is brutally concentrated — "there have been 296 cases of locally acquired dengue fever in Florida in 2026, with nearly 88% of those cases reported in Hillsborough County" (WTSP, via the dengue finding
).
The administrative clock is the story underneath the case count. Hillsborough and Pinellas had extended their local states of emergency until October 8 — today — and Pinellas has extended again (Pinellas County, via the dengue finding). Mosquito control has already cost Hillsborough roughly $6 million, 20 mosquito pools across eight counties have tested positive, and local health officials told commissioners the real numbers are higher because lab results are still processing. Pinellas is also flagging increased West Nile activity in sentinel chickens — a second mosquito-borne threat stacking onto the same counties.
What to watch: Whether weekly case growth bends as mosquito season winds down — or whether this becomes a permanent Florida transmission cycle requiring a state-level declaration.
H5N1: the fall surge reaches a state that had dodged cattle infections for 2.5 years
The avian flu fall surge is no longer a poultry story. USDA APHIS confirmed H5 clade 2.3.4.4b in two Washington dairy herds this week — "These are the first confirmed case detections of HPAI in livestock in the State of Washington" (USDA APHIS, via the H5N1 finding
). The uncomfortable detail: both herds had consistently tested negative under the National Milk Testing Strategy's routine surveillance before showing clinical signs. The screening net caught nothing until the cows got sick.
This lands on top of the September poultry surge — roughly 620,000 birds lost in 30 days — and Cambodia's sixth human case of the year. A new-state cattle detection in October widens the 2026 fall picture beyond business as usual, and sequencing results will determine which clade is circulating.
What to watch: Sequencing results, whether neighboring states report herds, and any human exposure cases tied to the Washington operations.
Ebola: the largest DRC outbreak ever, and the exports are arriving
The Bundibugyo outbreak hit 8,728 confirmed cases and 4,205 deaths as of October 6 — a 48.2% crude case-fatality rate — after adding 775 cases in under two weeks, and WHO now calls it "the largest Ebola disease outbreak ever recorded in the Democratic Republic of the Congo irrespective of virus species" (WHO DON 619, via the Ebola finding
). The international footprint expanded this week: the Kenyan index patient died October 5 after flying Nairobi-ward from Kampala, and the Netherlands medevaced a positive healthcare worker on October 1.
The mortality math explains why this keeps growing — 264 of 372 recent deaths occurred in communities, not treatment centers, and contact tracing sits at 80.4% coverage against an 85% target. A dead imported case in Kenya and a treated responder in the EU are exactly the failure modes that expand an outbreak's map, even with WHO still rating global risk as low.
What to watch: EBO-PEP obeldesivir prophylaxis results (~1,000 contacts) — the only near-term countermeasure bet for a virus with no approved vaccine or specific treatment.
Drug approvals: ATOMIC delivers the biggest adjuvant number in colon cancer this year
The FDA's oncology desk moved on October 8 with an unusually strong result: atezolizumab (Tecentriq) plus chemo won approval for adjuvant Stage III dMMR colon cancer on ATOMIC data showing "The hazard ratio for the DFS comparison was 0.50 (95% CI: 0.35, 0.73; p-value 0.0001), and the median DFS was not reached (NR) in either arm" (FDA, via the Tecentriq finding
). Halving recurrence or death risk in the curative-intent, post-surgical setting is a large effect, and the label spans patients down to age 2 — rare for oncology. The review ran under Project Orbis with four international regulators.
Mifepristone: the FDA puts a date on the review that could roll back mail-order pills
In a late-Wednesday court filing in Louisiana, the administration committed to completing its mifepristone safety review by March 2027, with study results expected in December 2026. The design: "comparing a sample of 100,000 women who used mifepristone with a comparator group who received surgical abortions" (Reuters, via the mifepristone finding
). The FDA is also weighing petitions to reinstate the in-person dispensing requirement repealed in 2023 — the rule that enabled mail-order pills, which now account for 65% of US abortions. Louisiana's suit and a Texas/Florida challenge are paused pending the review.
What to watch: The December study results — the first hard signal of whether the review produces label changes, REMS restrictions, or an attempt at the 2000 approval itself.
What surprised us
- The surveillance gap H5N1 just exposed. Two herds passed the National Milk Testing Strategy's routine screening repeatedly, then showed up sick anyway. The program built to close the surveillance blind spot missed its first real test in a new state.
- The Hochul–Kennedy channel worked instantly while Pennsylvania's didn't. One emergency declaration bought a same-week call with the HHS Secretary and a direct line to the CDC Director; the other state's death counts are still publicly disputed. The variable isn't the outbreak — it's the politics.
- Dengue's October growth. Case counts kept climbing into the month when mosquito season should be winding down, and the virus is now detectable in pools across eight counties. The Cuban DENV-2 strain looks entrenched, not transient.
- ATOMIC's effect size. A hazard ratio of 0.50 in the adjuvant setting — halving recurrence risk after surgery — is the kind of number checkpoint inhibitors usually post in metastatic disease, not curative-intent colon cancer.
Open threads worth a vote
Science & Health Digest — what changed since last cycle
Since last time
- New — three sections with no prior coverage: dengue in Tampa Bay, H5N1 reaching Washington dairy herds, and the FDA's mifepristone review timeline. The drug-approvals slot also carries entirely new substance (Tecentriq replacing last cycle's Tukysa/Rhapsido items).
- Escalated — Measles: the outbreak hit a 35-year-high case count, Pennsylvania confirmed a fifth death, and the Hochul–Kennedy channel that opened last cycle actually delivered. Ebola: the DRC outbreak is now officially the largest ever recorded in that country, with exports landing in Kenya and the Netherlands.
- Disappeared — the obesity/petrelintide section, the Nobel chemistry wrap-up, and both of last cycle's approval items (Tukysa, Rhapsido) are gone from this briefing. Also dropped: the $128M Ebola vaccine-trial funding gap, Kenya's 67-contact monitoring watch, and the "surprised us" items on petrelintide's discontinuation rate and the BTK class.
- Demoted / Unchanged — nothing qualifies; every carried-over section grew.
Measles: the federal posture is now openly two-faced (Escalated)
The death-count gap you read about last cycle is still there — CDC counts 2 of Pennsylvania's now 5 deaths (the fifth confirmed September 30, an unvaccinated Lancaster County resident) — but the story has shifted from "will the CDC blink" to "the federal response is officially split." The national tally hit 3,887 cases as of October 1–2, the highest since 1990/1991 and already above all of 2025.
What's new is that the Hochul channel worked. After New York's disaster emergency, HHS says RFK Jr. offered support on a Tuesday call and connected her with CDC Director Erica Schwartz:
"No state can address this on its own, which is why the governor will partner with anyone who can support our efforts to protect New Yorkers."
— Reuters via Yahoo, via the measles finding+1
The contrast with Pennsylvania — which has resisted seeking CDC help after Kennedy disputed its death counts — is now the defining feature. The NYT reports CDC is offering states $100 million in measles support, so the machinery is funded even as the politics stay loaded. Last cycle's PAHO watch item has hardened: losing elimination status at the November review is now the default expectation.
What to watch: Whether the CDC tally absorbs Pennsylvania's five deaths before November — and whether Texas and Virginia's CDC-assistance requests proceed without the friction Pennsylvania got.
Dengue: Tampa Bay's outbreak is now bigger than any recent year (New)
Not covered last cycle; this is the biggest new public-health story in the briefing. Florida has 296 locally acquired dengue cases in 2026 against 62 in all of 2025, with 44 new cases in the first week of October alone:
"there have been 296 cases of locally acquired dengue fever in Florida in 2026, with nearly 88% of those cases reported in Hillsborough County"
— WTSP, via the dengue finding
The administrative clock matters as much as the count: Hillsborough and Pinellas's local emergencies ran to October 8, and Pinellas has extended again (Pinellas County, via the dengue finding). Mosquito control has cost Hillsborough roughly $6 million; 20 pools across eight counties are positive; officials say real numbers are higher pending lab processing. Pinellas is also flagging West Nile in sentinel chickens — a second mosquito-borne threat in the same counties.
What to watch: Whether weekly growth bends as mosquito season winds down — or whether this becomes a permanent Florida transmission cycle needing a state-level declaration.
H5N1: the fall surge reaches a state that had dodged cattle infections for 2.5 years (New)
New this cycle, and the surveillance failure is the point. USDA APHIS confirmed H5 clade 2.3.4.4b in two Washington dairy herds — "These are the first confirmed case detections of HPAI in livestock in the State of Washington" (USDA APHIS, via the H5N1 finding). Both herds had repeatedly tested negative under the National Milk Testing Strategy before showing clinical signs — the screening net caught nothing until the cows got sick.
Context: ~620,000 poultry lost in 30 days in the September surge, and Cambodia's sixth human case of the year.
What to watch: Sequencing results, neighboring-state herds, and any human exposure cases tied to the Washington operations.
Ebola: the largest DRC outbreak ever, and the exports are arriving (Escalated)
Last cycle the story was Kenya's index patient dying and a "chaotic" response; both are now absorbed into a bigger fact. The Bundibugyo outbreak hit 8,728 confirmed cases and 4,205 deaths as of October 6 (48.2% CFR) after adding 775 cases in under two weeks, and WHO now calls it "the largest Ebola disease outbreak ever recorded in the Democratic Republic of the Congo irrespective of virus species" (WHO DON 619, via the Ebola finding).
The international footprint widened: the Kenyan patient died October 5 (flying Nairobi-ward from Kampala), and the Netherlands medevaced a positive healthcare worker October 1. The mortality math explains the growth — 264 of 372 recent deaths occurred in communities, and contact tracing sits at 80.4% coverage against an 85% target. WHO still rates global risk as low. Note: the $128M vaccine-trial funding gap from last cycle is no longer tracked here; the near-term bet is now framed entirely around obeldesivir.
What to watch: EBO-PEP obeldesivir prophylaxis results (~1,000 contacts) — the only near-term countermeasure test for a virus with no approved vaccine or specific treatment.
Drug approvals: ATOMIC delivers the biggest adjuvant number in colon cancer this year (New)
Entirely new substance — last cycle's Tukysa and Rhapsido approvals are not carried forward. The FDA approved atezolizumab (Tecentriq) plus chemo for adjuvant Stage III dMMR colon cancer on October 8:
"The hazard ratio for the DFS comparison was 0.50 (95% CI: 0.35, 0.73; p-value 0.0001), and the median DFS was not reached (NR) in either arm"
— FDA, via the Tecentriq finding
Halving recurrence or death risk in the curative-intent, post-surgical setting is a large effect; the label spans patients down to age 2, and the review ran under Project Orbis with four international regulators.
Mifepristone: the FDA puts a date on the review that could roll back mail-order pills (New)
New section, and the first hard timeline on a story that had been open-ended. In a late-Wednesday Louisiana court filing, the administration committed to completing its mifepristone safety review by March 2027, with study results expected December 2026:
"comparing a sample of 100,000 women who used mifepristone with a comparator group who received surgical abortions"
— Reuters, via the mifepristone finding
The FDA is also weighing petitions to reinstate the in-person dispensing requirement repealed in 2023 — the rule behind mail-order pills, now 65% of US abortions. Louisiana's suit and a Texas/Florida challenge are paused pending the review.
What to watch: The December study results — the first signal of whether this produces label changes, REMS restrictions, or an attempt at the 2000 approval itself.
What surprised us
- The surveillance gap H5N1 just exposed. [NEW] Two herds passed the National Milk Testing Strategy's routine screening repeatedly, then showed up sick anyway. The program built to close the surveillance blind spot missed its first real test in a new state.
- The Hochul–Kennedy channel worked instantly while Pennsylvania's didn't. [UPDATED — sharpens last cycle's observation about the inconsistent federal posture] One emergency declaration bought a same-week call with the HHS Secretary and a direct line to the CDC Director; the other state's death counts are still publicly disputed. The variable isn't the outbreak — it's the politics.
- Dengue's October growth. [NEW] Case counts kept climbing into the month when mosquito season should be winding down, and the virus is now detectable in pools across eight counties. The Cuban DENV-2 strain looks entrenched, not transient.
- ATOMIC's effect size. [NEW] A hazard ratio of 0.50 in the adjuvant setting — halving recurrence risk after surgery — is the kind of number checkpoint inhibitors usually post in metastatic disease, not curative-intent colon cancer.
Open threads
The previous briefing had no formal threads section — its watches lived in per-section "What to watch" lines. Status:
- Closed/absorbed: the Nobel chemistry wrap (thread resolved last cycle, now dropped); Kenya's 67-contact monitoring watch (the Kenyan case is now covered via the Ebola exports narrative).
- Still live, carried in the body: CDC tally vs. Pennsylvania's five deaths ahead of the November PAHO review (measles section).
- Dropped without resolution: the $128M Bundibugyo vaccine-trial funding gap and the remibrutinib RemIND program watch.
- New thread added: